These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 37856215)

  • 1. Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022.
    Contag CA; Mische L; Fong I; Karan A; Vaidya A; McCormick DW; Bower W; Hacker JK; Johnson K; SanJuan P; Crebbin L; Temmins C; Sahni H; Bogler Y; Cooper JD; Narasimhan S
    Emerg Infect Dis; 2023 Dec; 29(12):2520-2523. PubMed ID: 37856215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tecovirimat Resistance in Mpox Patients, United States, 2022-2023.
    Smith TG; Gigante CM; Wynn NT; Matheny A; Davidson W; Yang Y; Condori RE; O'Connell K; Kovar L; Williams TL; Yu YC; Petersen BW; Baird N; Lowe D; Li Y; Satheshkumar PS; Hutson CL
    Emerg Infect Dis; 2023 Dec; 29(12):2426-2432. PubMed ID: 37856204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential therapeutic targets for Mpox: the evidence to date.
    Byrareddy SN; Sharma K; Sachdev S; Reddy AS; Acharya A; Klaustermeier KM; Lorson CL; Singh K
    Expert Opin Ther Targets; 2023; 27(6):419-431. PubMed ID: 37368464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: potential impact on smallpox outbreak response capabilities, and future tecovirimat development potential.
    Russo AT; Grosenbach DW; Honeychurch KM; Long PG; Hruby DE
    Expert Rev Anti Infect Ther; 2023 Mar; 21(3):235-242. PubMed ID: 36728515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tecovirimat Treatment of People With HIV During the 2022 Mpox Outbreak : A Retrospective Cohort Study.
    McLean J; Stoeckle K; Huang S; Berardi J; Gray B; Glesby MJ; Zucker J
    Ann Intern Med; 2023 May; 176(5):642-648. PubMed ID: 37126820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tecovirimat for the treatment of severe Mpox in Germany.
    Hermanussen L; Brehm TT; Wolf T; Boesecke C; Schlabe S; Borgans F; Monin MB; Jensen BO; Windhaber S; Scholten S; Jordan S; Lütgehetmann M; Wiesch JSZ; Addo MM; Mikolajewska A; Niebank M; Schmiedel S
    Infection; 2023 Oct; 51(5):1563-1568. PubMed ID: 37273167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Distribution of Tecovirimat During the Peak of the Mpox Outbreak - Los Angeles County, June 2022-January 2023.
    O'Neil MJ; Archer R; Danza P; Fisher R; Bagwell DA; Younis I; Kulkarni S; Rubin Z; Kim M; Balter S; Terashita D; Kim J; Singhal R; Hancz D; Gausche-Hill M; Shah NK
    MMWR Morb Mortal Wkly Rep; 2024 Jun; 73(24):546-550. PubMed ID: 38900699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged Mpox Disease in People With Advanced HIV: Characterization of Mpox Skin Lesions.
    O'Shea J; Zucker J; Stampfer S; Cash-Goldwasser S; Minhaj FS; Dretler A; Cheeley J; Chaudhuri S; Gallitano SM; Gunaratne S; Parkinson M; Epling B; Morcock DR; Sereti I; Deleage C
    J Infect Dis; 2024 Mar; 229(Supplement_2):S243-S248. PubMed ID: 38019806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Tecovirimat Treatment for Mpox Disease Among People With HIV.
    Aldred B; Lyles RH; Scott JY; Gromer DJ; Aldredge A; Workowski KA; Wiley Z; Titanji BK; Szabo B; Sheth AN; Rebolledo PA; Nguyen ML; Marconi VC; Kelley CF; Kandiah S; Kalapila A; Jacob JT; Hall B; Colasanti JA; Cartwright EJ; Cantos VD
    JAMA Intern Med; 2024 Mar; 184(3):275-279. PubMed ID: 38190312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mpox in the New York metropolitan area, Summer 2022.
    Gnanaprakasam R; Keller M; Glassman R; El-Khoury MY; Chen DS; Feola N; Feldman J; Chaturvedi V
    J Med Virol; 2023 Apr; 95(4):e28699. PubMed ID: 36951318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trifluridine for treatment of mpox infection in drug combinations in ophthalmic cell models.
    Cinatl J; Bechtel M; Reus P; Ott M; Rothweiler F; Michaelis M; Ciesek S; Bojkova D
    J Med Virol; 2024 Jan; 96(1):e29354. PubMed ID: 38180134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance of Complicated Mpox Cases Unresponsive to Oral Tecovirimat in Los Angeles County, 2022.
    Karan A; Shah N; Garrigues JM; Alarcόn J; Hemarajata P; Finn LE; Poortinga K; Danza P; Kulkarni S; Kim M; Terashita D; Green NM; Balter S
    J Infect Dis; 2024 Mar; 229(Supplement_2):S249-S254. PubMed ID: 37995310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations.
    Frenois-Veyrat G; Gallardo F; Gorgé O; Marcheteau E; Ferraris O; Baidaliuk A; Favier AL; Enfroy C; Holy X; Lourenco J; Khoury R; Nolent F; Grosenbach DW; Hruby DE; Ferrier A; Iseni F; Simon-Loriere E; Tournier JN
    Nat Microbiol; 2022 Dec; 7(12):1951-1955. PubMed ID: 36344621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mpox in Children: 3 Cases.
    Frantzis I; Ungar SP; Soma VL; Knutsen D; Mazo D; Zucker J
    Pediatrics; 2024 Jan; 153(2):. PubMed ID: 38239109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Case of Neonatal Monkeypox Treated With Oral Tecovirimat.
    Castejon-Ramirez S; Pennington J; Beene H; Hysmith N; Ost S
    Pediatrics; 2024 Jan; 153(1):. PubMed ID: 38148743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical considerations on monkeypox antiviral medications: An overview.
    Pourkarim F; Entezari-Maleki T
    Pharmacol Res Perspect; 2024 Feb; 12(1):e01164. PubMed ID: 38149674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection.
    Nguyen BT; Marc A; Suñer C; Marks M; Ubals M; Hernández-Rodríguez Á; Melendez MÁ; ; Hruby DE; Russo AT; Mentré F; Mitjà O; Grosenbach DW; Guedj J
    PLoS Biol; 2023 Dec; 21(12):e3002249. PubMed ID: 38127878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and Pilot of an Mpox Severity Scoring System.
    Zucker J; McLean J; Huang S; DeLaurentis C; Gunaratne S; Stoeckle K; Glesby MJ; Wilkin TJ; Fischer W; Damon I; Brooks JT
    J Infect Dis; 2024 Mar; 229(Supplement_2):S229-S233. PubMed ID: 37956401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibility of eighteen clinical isolates of human monkeypox virus to tecovirimat.
    Nunes DDS; Higa LM; Oliveira RL; da Costa LC; Bomfim LM; Gonçalves CCA; Mariani D; Hruby DE; Voloch CM; Castiñeiras TMPP; Tanuri A; Damaso CR
    Mem Inst Oswaldo Cruz; 2023; 118():e230056. PubMed ID: 37436275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-Healing Corneal Ulcer and Uveitis Following Monkeypox Disease: Diagnostic and Therapeutic Challenges.
    Androudi S; Kaufman AR; Kouvalakis A; Mitsios A; Sapounas S; Al-Khatib D; Schibler M; Pineda R; Baglivo E
    Ocul Immunol Inflamm; 2024 Apr; 32(3):253-258. PubMed ID: 37140328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.